innoVitro – Contractility-Based Pharmacological Characterization of hiPSC-Derived Atrial and Ventricular Cardiomyocytes for Preclinical Toxicity Testing

The poster by innoVitro Contractility-Based Pharmacological Characterization of hiPSC-Derived Atrial and Ventricular Cardiomyocytes for Preclinical Toxicity Testing presents a comparative study of Axol Bioscience’s chamber-specific cardiomyocytes using the FLEXcyte 96 platform.

Key highlights include:

• Cell Types: Atrial and ventricular cardiomyocytes derived from a healthy 74-year-old male donor
• Platform: FLEXcyte 96 system with fibronectin-coated ultra-thin PDMS membranes mimicking native heart mechanics
• Assay Parameters:
  • Contractile force (mN/mm²)
  • Beat rate
  • Beat duration 90 (BD90)
  • Contraction/relaxation slopes and AUC
  • Arrhythmic events
• Pharmacological Profiling:
  • S-Bay K8644: Opposing effects on atrial vs. ventricular cells
  • Carbachol & Acetylcholine: Atrial-specific responses due to I_KACh expression
  • Other compounds: Ivabradine, vernakalant, 4-AP tested across dose ranges
• Chamber-Specific Findings:
  • Atrial cells: Shorter BD90, higher beat rate
  • Ventricular cells: Stronger contraction force
• Heatmap Analysis: Visualizes compound effects across multiple contractility metrics

This model supports predictive cardiac safety screening and subtype-specific disease modeling.

Featured Axol Products:

• axoCells™ Ventricular Cardiomyocytes – ax2508
• axoCells™ Atrial Cardiomyocytes – ax2518